ANAB Anaptysbio Earnings and EPS analysis

Relative Growth: Rel. Growth: 96

Relative Strength: Rel. Strength: 41

Relative Valuation: Rel. Valuation: 79

Relative Profitability: Rel. Profitability: 99

EPS in 2026 (TTM): $6.76

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the EPS for the trailing twelve months is $6.76. Anaptysbio's EPS for 2025 amounted to -$0.46, marking an increase from -$5.12 in 2024. During the quarterly period ending on Jun 30, 2026, ANAB's EPS stood at $6.36.

ANAB earnings history

Historical annual and quarterly earnings per share (EPS) data for Anaptysbio

EPS (TTM)

$6.76

EPS Growth YoY (Quarterly)

574.6%

EPS (Quarterly)

$6.36

EPS Growth (Quarterly)

445.7%

Anaptysbio had an annual EPS of -$0.46, indicating an increase of 91% from -$5.12 in 2024. The quarterly per-share earnings for the period ending Jun 30, 2026, was $6.36, indicating a 574.6% increase from the same quarter last year. ANAB's 12-month EPS stands at $6.76 as of June 2026. Anaptysbio's annual EPS in 2024 stood at -$5.12, a 15.8% increase year-over-year.

ANAB EPS vs price chart

ANAB EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

574.6%

EPS growth YoY

91%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

During the last 12 months, Anaptysbio has seen an EPS growth of 574.6% (YoY, quarterly).

ANAB Earnings Waterfall

Breakdown of revenue, profit and net income for Anaptysbio

ANAB Earnings vs Peers

What are the earnings of ANAB compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
ORMP Oramed Pharmaceuticals Inc	0.95	418.8%	N/A	N/A
ANAB Anaptysbio Inc	6.94	91%	N/A	N/A
OMER Omeros Corp	9.34	98.1%	N/A	N/A
OLMA Olema Pharmaceuticals Inc	N/A	15%	N/A	N/A
VIVS VivoSim Labs Inc.	N/A	-214.7%	N/A	N/A
ORIC Oric Pharmaceuticals Inc	N/A	19.7%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.